Literature DB >> 30151723

Multi-dimensional Assessment of IPF Across a Wide Range of Disease Severity.

Hana Serajeddini1, Paola Rogliani2, Marco Mura3,4,5.   

Abstract

PURPOSE: The pathophysiology of idiopathic pulmonary fibrosis (IPF) is complex, and its clinical course is difficult to predict. Perceived dyspnea, exercise capacity, and lung physiology have all been associated with mortality outcomes in IPF, but the significance of these relationships is unclear. We sought to investigate the correlation among these variables and their independent predictive capability in determining mortality outcomes.
METHODS: Four-hundred-thirty-seven patients diagnosed with IPF from three independent centers were included in the study. Medical Research Council Dyspnea Score (MRCDS), 6-min walk distance (6MWD), and pulmonary function tests were determined at baseline. The end-point was 18-month transplant-free survival.
RESULTS: Correlations between MRCDS, 6MWD, forced vital capacity (FVC), and diffusing lung capacity for carbon monoxide were either very weak or weak. Calculation of variance inflation factors demonstrated absence of collinearity among these variables. Univariate regression analysis and c-statistics identified MRCDS, 6MWD, and FVC as significant predictors of 18-month transplant-free survival. Multivariate regression analysis retained MRCDS, 6MWD, and FVC as independent predictors of mortality. To ensure generalizability, we confirmed the results in subgroups of patients stratified according to baseline FVC, and further by considering lung transplant as a competing event to death.
CONCLUSIONS: In a cohort of patients with IPF encompassing a wide range of disease severity, baseline perceived exertional dyspnea, exercise capacity, and lung function are weakly correlated to each other, translating in the absence of collinearity. MRCDS, 6MWD, and FVC are significant and independent predictors of outcome, suggesting that a multi-dimensional assessment of IPF is prognostically appropriate and advantageous.

Entities:  

Keywords:  Dyspnea; Exercise capacity; Idiopathic pulmonary fibrosis; Outcome; Pulmonary function

Mesh:

Year:  2018        PMID: 30151723     DOI: 10.1007/s00408-018-0152-4

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  28 in total

1.  ATS statement: guidelines for the six-minute walk test.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2002-07-01       Impact factor: 21.405

2.  Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study.

Authors:  Marco Mura; Maria A Porretta; Elena Bargagli; Gianluigi Sergiacomi; Maurizio Zompatori; Nicola Sverzellati; Amedeo Taglieri; Fabrizio Mezzasalma; Paola Rottoli; Cesare Saltini; Paola Rogliani
Journal:  Eur Respir J       Date:  2012-01-12       Impact factor: 16.671

3.  6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.

Authors:  Roland M du Bois; Carlo Albera; Williamson Z Bradford; Ulrich Costabel; Jonathan A Leff; Paul W Noble; Steven A Sahn; Dominique Valeyre; Derek Weycker; Talmadge E King
Journal:  Eur Respir J       Date:  2013-12-05       Impact factor: 16.671

4.  A simple dyspnoea scale as part of the assessment to predict outcome across chronic interstitial lung disease.

Authors:  Hadeel Khadawardi; Marco Mura
Journal:  Respirology       Date:  2016-11-08       Impact factor: 6.424

Review 5.  Clinical course and prediction of survival in idiopathic pulmonary fibrosis.

Authors:  Brett Ley; Harold R Collard; Talmadge E King
Journal:  Am J Respir Crit Care Med       Date:  2010-10-08       Impact factor: 21.405

6.  Impact of pulmonary hemodynamics on 6-min walk test in idiopathic pulmonary fibrosis.

Authors:  Omar A Minai; Jose F Santacruz; Joan M Alster; Marie M Budev; K McCarthy
Journal:  Respir Med       Date:  2012-08-16       Impact factor: 3.415

7.  Functional predictors of exertional dyspnea, 6-min walking distance and HRCT fibrosis score in idiopathic pulmonary fibrosis.

Authors:  Marco Mura; Anna Ferretti; Orazio Ferro; Maurizio Zompatori; Alberto Cavalli; Mario Schiavina; Mario Fabbri
Journal:  Respiration       Date:  2005-11-07       Impact factor: 3.580

8.  Reference equations for the six-minute walk in healthy adults.

Authors:  P L Enright; D L Sherrill
Journal:  Am J Respir Crit Care Med       Date:  1998-11       Impact factor: 21.405

9.  A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.

Authors:  Talmadge E King; Williamson Z Bradford; Socorro Castro-Bernardini; Elizabeth A Fagan; Ian Glaspole; Marilyn K Glassberg; Eduard Gorina; Peter M Hopkins; David Kardatzke; Lisa Lancaster; David J Lederer; Steven D Nathan; Carlos A Pereira; Steven A Sahn; Robert Sussman; Jeffrey J Swigris; Paul W Noble
Journal:  N Engl J Med       Date:  2014-05-18       Impact factor: 91.245

10.  Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.

Authors:  Steven D Nathan; Carlo Albera; Williamson Z Bradford; Ulrich Costabel; Roland M du Bois; Elizabeth A Fagan; Robert S Fishman; Ian Glaspole; Marilyn K Glassberg; Kenneth F Glasscock; Talmadge E King; Lisa Lancaster; David J Lederer; Zhengning Lin; Carlos A Pereira; Jeffrey J Swigris; Dominique Valeyre; Paul W Noble; Athol U Wells
Journal:  Thorax       Date:  2016-03-11       Impact factor: 9.139

View more
  3 in total

1.  The CALIPER-Revised Version of the Composite Physiologic Index is a Better Predictor of Survival in IPF than the Original Version.

Authors:  Karishma S Hosein; Gianluigi Sergiacomi; Maurizio Zompatori; Marco Mura
Journal:  Lung       Date:  2019-12-02       Impact factor: 2.584

2.  Validation of the risk stratification score in idiopathic pulmonary fibrosis: study protocol of a prospective, multi-centre, observational, 3-year clinical trial.

Authors:  Gian Marco Manzetti; Karishma Hosein; Matthew J Cecchini; Keith Kwan; Mohamed Abdelrazek; Maurizio Zompatori; Paola Rogliani; Marco Mura
Journal:  BMC Pulm Med       Date:  2021-12-04       Impact factor: 3.317

3.  Associations between Patient-reported Outcomes and Death or Lung Transplant in Idiopathic Pulmonary Fibrosis. Data from the Idiopathic Pulmonary Fibrosis Prospective Outcomes Registry.

Authors:  Amy Hajari Case; Anne S Hellkamp; Megan L Neely; Shaun Bender; Daniel F Dilling; Mridu Gulati; David L Hotchkin; Tristan J Huie; Lisa Lancaster; Laurie D Snyder; Craig S Conoscenti; Scott M Palmer
Journal:  Ann Am Thorac Soc       Date:  2020-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.